US · LFMDP · MEDICAL - PHARMACEUTICALS
LifeMD, Inc. (LFMDP) intrinsic value and stock valuation
$18.00as of 2026-11-21 · Mkt cap 159.97M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
LifeMD, Inc. DCF and intrinsic value
InvestorsCraft values LFMDP with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from LFMDP’s statements →
LifeMD, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $194.1M | $212.5M | $152.6M | $119M | $92.9M |
| Operating income | -$-7.67M | -$-16.14M | -$-14.49M | -$-43.45M | -$-54.3M |
| Net income | -$-7.11M | -$-18.88M | -$-20.6M | -$-45.54M | -$-60.9M |
| EPSd | -$-157.54K | -$-458.25K | -$-607.49K | -$-1.47M | -$-2.25M |
| Operating cash flow | $8.28M | $17.5M | $8.82M | -$-22.94M | -$-33.09M |
| Capital expenditure | -$-9.52M | -$-11.54M | -$-8.73M | -$-12.89M | -$-3.4M |
| Free cash flow | -$-1.24M | $5.98M | $90K | -$-35.83M | -$-36.49M |
| Total assets | $70.4M | $72.5M | $58.5M | $25.7M | $49.9M |
| Total debt | $6.32M | $25.1M | $18.9M | $4.13M | $1.85M |
| Net debt | -$-30.46M | -$-9.9M | -$-14.21M | $170K | -$-39.48M |
| Total equity | $23.2M | -$-4.05M | $5.57M | -$-7.31M | $25.8M |
| Cash and short-term investments | $36.8M | $35M | $33.2M | $3.96M | $41.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $194.1M | $212.5M | $152.6M | $119M | $92.9M |
| Cost of revenue | $39.3M | $24.1M | $18.9M | $18.7M | $18M |
| Gross profit | $154.8M | $188.4M | $133.7M | $100.4M | $74.9M |
| Research and development expenses | $7.35M | $9.51M | $6.06M | $2.97M | $950K |
| Selling, general and administrative expenses | $144M | $175.7M | $128.2M | $125.3M | $122.1M |
| Other expenses | $11.1M | $19.3M | $13.9M | $15.5M | $6.16M |
| Operating expenses | $162.4M | $204.5M | $148.1M | $143.8M | $129.2M |
| Cost and expenses | $201.7M | $228.6M | $167M | $162.5M | $147.2M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $1.36M | $2.18M | $2.6M | $1.28M | $3.02M |
| Depreciation and amortization | $7.31M | $9.49M | $6.6M | $1.09M | $360K |
| Ebitda | -$-1.52M | -$-6.65M | -$-8.21M | -$-38.6M | -$-57.94M |
| Operating income | -$-7.67M | -$-16.14M | -$-14.49M | -$-43.45M | -$-54.3M |
| Total other income/expenses, net | -$-2.52M | -$-2.18M | -$-2.92M | -$-1.21M | -$-7.02M |
| Income before tax | -$-10.19M | -$-18.33M | -$-17.41M | -$-44.66M | -$-61.32M |
| Income tax expense | $50K | $400K | $430K | $360K | $10K |
| Net income | -$-7.11M | -$-18.88M | -$-20.6M | -$-45.54M | -$-60.9M |
| Weighted average shares outstanding | $45.1M | $41.2M | $33.9M | $31M | $27M |
| Weighted average diluted shares outstanding | $45.1M | $41.2M | $33.9M | $31M | $27M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $36.8M | $35M | $33.2M | $3.96M | $41.3M |
| Net receivables | $9.31M | $8.22M | $5.28M | $2.83M | $980K |
| Inventory | $2.77M | $2.8M | $2.76M | $3.7M | $1.62M |
| Total current assets | $51.8M | $48.7M | $42.6M | $11.3M | $44.9M |
| Property, plant and equipment, net | $5.27M | $7.88M | $1.07M | $1.68M | $1.99M |
| Goodwill and intangible assets | $260K | $15.9M | $14.8M | $12.7M | $3.02M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $18.6M | $23.7M | $15.9M | $14.4M | $5M |
| Total assets | $70.4M | $72.5M | $58.5M | $25.7M | $49.9M |
| Accounts payable | $14.2M | $16M | $11.1M | $10.1M | $9.06M |
| Short-term debt | $640K | $8.95M | $930K | $3.55M | $670K |
| Deferred revenue | $10.8M | $14.5M | $8.83M | $5.55M | $1.5M |
| Total current liabilities | $41.6M | $60.3M | $34.8M | $31.4M | $22.8M |
| Long-term debt | $5.68M | $16.2M | $18M | $570K | $1.18M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $5.68M | $16.3M | $18.1M | $1.6M | $1.28M |
| Capital lease obligations | $6.32M | $6.77M | $680K | $1.33M | $1.79M |
| Total liabilities | $47.3M | $76.5M | $52.9M | $33M | $24.1M |
| Common stock | $470K | $420K | $380K | $320K | $310K |
| Retained earnings | -$-228.6M | -$-236.25M | -$-214.27M | -$-190.56M | -$-141.92M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $23.2M | -$-4.05M | $5.57M | -$-7.31M | $25.8M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $6.32M | $25.1M | $18.9M | $4.13M | $1.85M |
| Net debt | -$-30.46M | -$-9.9M | -$-14.21M | $170K | -$-39.48M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $15.6M | -$-18.73M | -$-20.6M | -$-45.02M | -$-61.32M |
| Depreciation and amortization | $330K | $9.49M | $6.6M | $3.77M | $870K |
| Stock-based compensation | $10.5M | $12.2M | $12.5M | $13.7M | $12.1M |
| Change in working capital | -$-7.85M | $12.7M | $4.91M | -$-1.55M | $9.13M |
| Accounts receivable | $1.15M | -$-2.94M | -$-2.44M | -$-2.19M | $20K |
| Inventory | $300K | $680K | $760K | -$-2.18M | -$-410K |
| Accounts payable | $3.24M | $4.92M | $980K | $1.25M | -$-890K |
| Net cash provided by operating activities | $8.28M | $17.5M | $8.82M | -$-22.94M | -$-33.09M |
| Investments in property, plant and equipment | -$-1.87M | -$-1.49M | -$-200K | -$-370K | -$-250K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-1.01M | $0.00 |
| Net cash used for investing activities | $6.91M | -$-11.54M | -$-8.73M | -$-13.91M | -$-3.4M |
| Common stock issued | $9.19M | $0.00 | $16.2M | $0.00 | $14M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-3.11M | -$-3.11M | -$-3.11M | -$-3.11M | -$-870K |
| Net cash used for financing activities | -$-13.41M | -$-4.12M | $29.1M | -$-530K | $68.6M |
| Net change in cash | $1.78M | $1.86M | $29.2M | -$-37.37M | $32.2M |
| Cash at end of period | $36.8M | $35M | $33.2M | $3.96M | $41.3M |
| Operating cash flow | $8.28M | $17.5M | $8.82M | -$-22.94M | -$-33.09M |
| Capital expenditure | -$-9.52M | -$-11.54M | -$-8.73M | -$-12.89M | -$-3.4M |
| Free cash flow | -$-1.24M | $5.98M | $90K | -$-35.83M | -$-36.49M |
Line items
Line items
Line items
About LifeMD, Inc.
LifeMD, Inc. functions as a direct-to-patient telehealth enterprise, linking individuals with healthcare professionals throughout the United States for a diverse array of medical concerns. These services encompass everything from personalized concierge care to specialized fields such as men's sexual health and dermatology. The company operates a portfolio of distinct telehealth brands. ShapiroMD is dedicated to comprehensive hair loss solutions, offering virtual consultations, prescription medications, unique over-the-counter products, an FDA-approved medical device, and specialized compounded topical treatments for both male and female hair loss. RexMD provides virtual medical treatment from licensed providers for various men's health requirements. LifeMD Primary Care is a subscription-based, mobile-first platform delivering personalized virtual primary, urgent, and chronic care, integrating online consultations, prescription services, diagnostics, and imaging. Cleared focuses on customized treatments for allergy, asthma, and immunological conditions. Nava MD serves as a female-oriented tele-dermatology and skincare brand, facilitating virtual medical consultations with dermatologists and other experts. Beyond its healthcare focus, LifeMD also manages PDFSimpli, an online software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents. The company distributes its products and services directly to consumers, through e-commerce channels, and via third-party partner networks. Initially established in 1994 as Conversion Labs, Inc., the company officially rebranded to LifeMD, Inc. in February 2021. Its corporate headquarters are located in New York, New York.
- CEO
- Justin Schreiber
- Employees
- 389
- Beta
- 2.06
Explore
Frequently asked questions
What is the intrinsic value of LifeMD, Inc. (LFMDP)?
LifeMD, Inc. (LFMDP) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LFMDP undervalued?
LFMDP trades at a price of $18.00 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.